# KLOW peptide — four peptides, one vial, no blend study | KLOW Online

> KLOW peptide is a research-only blend of four peptides: KPV, GHK-Cu, BPC-157 and TB-500. The blend itself has never been tested in a controlled study. Cited, plain-English summaries.

Four peptides in one vial: KPV, GHK-Cu, BPC-157, TB-500. Four separate marks. Each one studied alone. The combination, never. We read them one at a time.

## The short version

**KLOW peptide** is a research-only blend of four peptides mixed into one vial. The four are KPV, GHK-Cu, BPC-157 and TB-500. They stay four separate molecules — KLOW is not one new drug, it is four things dissolved together.

Each one was studied on its own, mostly in cells and rats. KPV calms inflammation. GHK-Cu (a copper-carrying peptide) helps skin make collagen. BPC-157 helps gut and tendon tissue heal in animals. TB-500 helps wounds close. Put together, the idea is that they cover four steps of repair at once.

But here is the honest part: no study has ever tested the four-peptide KLOW blend itself. Every "they work better together" claim is a guess built from the single-peptide research, not proof. KLOW is not a weight-loss drug, and it is not FDA-approved. What people report — the upsides and the downsides — is on [benefits and reported effects](/effects).

## What is KLOW peptide?

KLOW is a research-only co-formulation of four distinct peptides: KPV, GHK-Cu, BPC-157 and TB-500. They are co-dissolved in one vial at fixed mass ratios. They do not fuse into a single chemical entity — four molecules share the vial, nothing more [1].

The most widely listed research-vial composition is an 80 mg total: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg. There is no FDA-approved or pharmacopeial KLOW product. It is supplied strictly as a research-chemical co-formulation.

KLOW carries no single CAS number, no single molecular weight, no single PubChem entry. A mixture has no identity of its own. Each constituent has its own identifiers; the blend has none.

## KLOW as a four-peptide co-formulation

Four peptides. Four jobs. One cascade of tissue repair.

- **KPV** — the anti-inflammatory arm. A tripeptide, Lys-Pro-Val, the tail end of alpha-MSH (a hormone that, among other things, dials down inflammation). It suppresses NF-kB (a master switch for inflammatory genes) and lowers inflammatory signals in cells [2].
- **GHK-Cu** — the matrix arm, and the mass-dominant one. About 62.5% of the canonical vial. A copper-carrying tripeptide that pushes cells to build collagen and that shifts a large slice of the genes a skin cell uses [7][8].
- **BPC-157** — the blood-vessel and connective-tissue arm. A 15-amino-acid peptide that, in rats, speeds tendon and gut healing and grows new vessels [5][4].
- **TB-500** — the cytoskeleton arm. A short fragment of thymosin beta-4 that binds actin, a step tied to cells crawling into a wound [6].

The rationale for combining them is mechanistic: four non-overlapping nodes of one repair network. Mechanistic is the right word — and the limit. No study tested the four-peptide blend together [1].

## What is in the 80 mg KLOW vial?

The most widely listed composition: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg = 80 mg total.

GHK-Cu is mass-dominant — roughly 62.5% of the vial. The other three split the rest evenly. The four are co-dissolved at fixed ratios but remain separate molecules; the vial is a mixture, not a compound [1].

A note that follows from the chemistry, not from any blend study: the four peptides clear the body at very different speeds. BPC-157 has a very short elimination half-life — under about 30 minutes in the formal study — and the two tripeptides clear even faster [9]. One co-dissolved dose cannot hold all four at matched levels. The full picture is on the [doses used in the component research](/dosage).

## What does the KLOW peptide do?

Its four arms occupy non-overlapping nodes of one tissue-repair network. KPV suppresses inflammatory transcription [2]. GHK-Cu drives collagen and matrix synthesis and supplies copper for the enzymes that crosslink collagen [7]. BPC-157 promotes angiogenesis (the growth of new blood vessels) and connective-tissue repair in animals [5][3]. TB-500, through the actin-binding motif of thymosin beta-4, aids cell migration and wound closure [6].

That combined action is a rationale, not a result. No controlled study has tested the four together [1]. For what the published single-component literature actually measured, read the [published study findings](/research).

---

Four peptides set down as four separate marks, each read against its own studies — with the missing combination data left as the one honest blank, and nothing here clinical, prescribed, or for sale.